Antibody Therapeutics Patients First!


2019 Bio Connection Australia
  • 글쓴이 관리자
  • 작성일 2019-07-01 13:10:23
  • 조회수 13382
첨부파일 Informa-Bio-Connections_(주)파멥신.pdf

PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and

Chief Executive Officer of PharmAbcine is invited as keynote speaker and panelist to give a presentation and

panel discussion at Bio Connection Australia organized by INFORMA in Melbourne on August 19th-20th, 2019 

( ) 

Dr. Yoo will share the experience as follows:
1. Olinvacimab (previously Tanibirumab or TTAC-0001) Phase IIa with recurrent GBM trials completed on June 2017
(the last patient release) and completed with its CSR(Clinical Study Report) on March 2018.
2. Olinvacimab + Keytruda combo phase Ib with metastatic Triple Negative Breast Cancer ongoing trial.
3. Olinvacimab + Keytruda combo phase Ib with recurrent GBM ongoing trial. 

He also will share the preparation for next coming trials.

4. Olinvacimab phase II Avastin recurrent/relapsed recurrent GBM at Olivia Newton John Cancer Center
in Melbourne joint trials with Stanford University Cancer Center and Florida Cancer Center in the States.
5.  Olinvacimab + Keytruda combo phase II with metastatic Triple Negative Breast Cancer global trial including Australia.

6.  Olinvacimab + Keytruda combo phase II with recurrent GBM global trial including Australia.  

더 자세한 내용을 원하시면, 첨부된 파일로 확인 가능합니다.

다음글 2019 Scripps Korea Society Symposium